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Abstract.
Background: DNA double strand breaks are the cytotoxic lesions produced by ionising radiation. Critical for the repair of
these lesions is the DNA damage response protein MRE11 which, in a complex with RAD50 and NBS1, mediates DNA
damage signalling and double-strand break repair. We previously found the presence of an MRE11 germline single nucleotide
polymorphism (SNP), rs1805363 (G > A), to be associated with poor outcome following radiotherapy (RT) and increased
expression of MRE11 isoform 2 in a limited panel of bladder cancer cell lines and tumours.
Objectives: To look for further evidence in support of the SNP/isoform association in a larger panel of germline and tumour
samples donated by patients diagnosed with invasive bladder cancer, and to test the hypothesis that bladder cancer cells
expressing MRE11 isoform 2 would be more radio resistant than cells expressing MRE11 isoform 1.
Methods: Germline DNA from 189 patients with invasive bladder cancer (141 T2, 48 T1) was genotyped for the rs1805363
G > A SNP. Loss of heterozygosity was determined by genotyping tumour DNA in 17GA germline patients. The Cancer
Genome Atlas was mined to correlate presence of the GA germline genotype with MRE11 isoform expression. We used
colony formation assays and H2AX foci kinetics after ionising radiation in RT112 MRE11 knockdown cells expressing
ectopic MRE11 isoform 1 or 2.
1These authors contributed equally to this work.
∗Correspondence to: Professor Anne E. Kiltie, CRUK/MRC
Oxford Institute for Radiation Oncology, Department of Oncol-
ogy, Off Roosevelt Drive, Oxford OX3 7DQ, UK. Tel.: +44 1865
617352; E-mail: anne.kiltie@oncology.ox.ac.uk and Dr Roland
Arnold, The Institute of Cancer and Genomic Sciences, Univer-
sity of Birmingham, Birmingham B15 2SY, UK. Tel.: +44 121
4149119; E-mail: r.arnold.2@bham.ac.uk.
ISSN 2352-3727/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0).
148 A.K. Walker et al. / MRE11 Isoform Expression in Radiation Response
Results: Of the 189 germline DNA samples, 22 contained both the A minor allele and G major allele with the remaining wild
type containing only the G major allele. LOH was identified in seven of 17 available tumour samples. Tumour MRE11 isoform
2 expression was found to be significantly higher (p = 0.007) in patients’s samples containing the A minor allele compared
to those with only the G major allele (n = 23). In the TCGA database we found 16% (66 out of 406) of bladder tumours
heterozygous for the SNP and only two homozygous, and a significant relative increase of isoform 2 usage (p = 0.017). We
identified no significant difference in radio sensitivity between bladder cancer cells expressing either MRE11 isoform.
Conclusions: In this study the MRE11 isoform 2 was not found to be associated with increased cellular sensitivity to
radiation. We conclude that the previously reported association between the germline rs1805363 SNP and poor survival in
MIBC patients following RT is unlikely to be related to the DNA damage response function of MRE11 isoform 2.
Keywords: Bladder cancer, MRE11, rs1805363, MRE11 isoform 1, MRE11 isoform 2
INTRODUCTION
Organ-confined muscle-invasive bladder cancer
(MIBC) is routinely treated using either radical
cystectomy or bladder-sparing approaches includ-
ing chemoradiotherapy (CRT) or radiotherapy alone,
with or without neoadjuvant chemotherapy. Cystec-
tomy and radiotherapy have been shown to result
in similar cause-specific survival rates [1] but no
randomised trial has successfully compared the two
modalities. Predictive biomarkers that could aid treat-
ment decision making would be useful in this setting
and could potentially increase patient survival rates.
DNA double strand breaks (DSB) are the cytotoxic
lesions caused by ionising radiation and are repaired
via two major pathways: non-homologous end join-
ing and homologous recombination [2–4]. MRE11 is
a DNA damage response protein which can bind DNA
and which possesses endo- and exonuclease activity.
Many of the functions of MRE11 are reliant on its
ability to form a complex with Nijmegen breakage
syndrome 1 (NBS1) and RAD50, the MRN complex.
The MRN complex is involved in both the recogni-
tion of DSBs, enhancing the rate of ATM activation
and subsequent DNA damage signalling [5–9], and
the repair of DSBs through its role as a nuclease
in homologous recombination [10, 11]. The alter-
native splicing of MRE11 results in two transcript
variants encoding MRE11 isoform 1 and MRE11 iso-
form 2, respectively. The two MRE11 isoforms are
similar, with the only difference in the translated pro-
tein being the absence of a short 27 amino-acid-long
exon, exon 16, in MRE11 isoform 2. At the transcript
level MRE11 isoform 2 has a longer 5’ UTR than the
MRE11 isoform 1.
We have previously shown that high tumour
protein levels of MRE11, as determined by immuno-
histochemistry, were associated with improved
patient outcome following radio therapy in MIBC
patients [12, 13]. Using next generation sequencing,
we also identified a single nucleotide polymorphism
(SNP) within MRE11 (rs1805363) which was asso-
ciated with worse cancer-specific survival following
radiotherapy [14]. The rs1805363 SNP is a germline
MRE11 variant (G to A transition) which is located
intronically in MRE11 isoform 1, five bases 3’ to the
exon 1 AG donor splice site, and in MRE11 isoform
2 is located within the 5’UTR. In a panel of bladder
cancer cell lines and three patient tumour samples,
the presence of the rs1805363 A minor allele was
found to correlate with an increase in the expression
of MRE11 isoform 2 over MRE11 isoform 1 [14].
Here, we sought to validated our previous finding
that the presence of the rs1805363 A minor allele cor-
relates with higher MRE11 isoform 2 expression in
patients with invasive bladder cancer by examining
a larger number of tumour samples for the propor-
tion of isoform 2 relative to isoform 1 expression.
In addition, we mined variation and expression data
from the TCGA bladder cancer cohort for the rela-
tionship of MRE11 isoform usage and rs1805363.
We also tested the hypothesis that bladder cancer
cells expressing MRE11 isoform 2 would be more
radioresistant than cells expressing MRE11 isoform
1. We generated cell lines which expressed anMRE11
construct containing the coding sequence of MRE11
isoform 1 or MRE11 isoform 2, and then used the
cells in assays to determine cellular radiosensitivity
and DSB repair efficiency.
MATERIALS AND METHODS
Patient materials
Germline DNA, extracted tumour DNA and
FFPE bladder cancer biopsies were obtained from
participants in the Bladder Cancer Prognosis Pro-
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gramme (University of Birmingham, UK) under
ethical approval (06/MRE04/65) [15] BCPP partic-
ipants were recruited between 2005 and 2011, and
gave informed consent for enrolment into BCPP
on the basis of initial cystoscopic findings sugges-
tive of primary bladder cancer. All patients were
newly-diagnosed, had not received treatment prior
to biospecimen collection, and were subsequently
treated and followed-up according to contemporary
guidelines (including re-resection where indicated).
Inclusion and exclusion criteria are detailed else-
where [15].
Genotyping the RS1805363 SNP
A predesigned TaqMan SNP Genotyping assay
(C 11474841 10) (Applied Biosystems-Thermo
Fisher Scientific, Foster City, CA, USA) was used
with a 7500 Fast Real Time PCR system under
standard genotyping parameters to genotype patient
DNA. Analysis was conducted using 7500 software.
RNA extraction
Ten-micron thick tissue sections plus an additional
4m thick tissue section were cut from FFPE blad-
der cancer biopsies. Four micron sections were H&E
stained and sent to a Consultant Uropathologist (LB)
to demarcate invasive areas of tumour tissue. Ten
micron sections were placed at –20◦C and stored
until microdissection, with storage at –20◦C lim-
ited to a maximum of 3 weeks. For each patient
sample, invasive tumour tissue was scraped from
10 × 10m tissue sections and placed in a ster-
ile Eppendorf tube using a 15C carbon steel sterile
scalpel blade (Swann Morton). Macrodissected tissue
was then immediately subjected to RNA extrac-
tion using an RNeasy FFPE kit (Qiagen, Venlo,
Netherlands) with deparaffinisation solution (Qia-
gen, Venlo, Netherlands). Successful RNA extraction
was confirmed by running 5l of RNA on a 1%
agarose (Sigma Aldrich, St. Louis, MO, USA) gel.
RNA was converted into cDNA using a High-
Capacity cDNA reverse transcription kit with RNase
inhibitor (Applied Biosystems-Thermo Fisher Scien-
tific, Waltham, CA, USA).
Quantiﬁcation of MRE11 isoforms
Primers were designed (Forward- GGACTTGAA
GCATCTACGTT, Reverse- ATGCGATTCCTAAA
TTACCC) to flank the MRE11 rs1805363 G > A
SNP, resulting in polymerase chain reaction (PCR)
fragment sizes of 144bp for MRE11 isoform 1 and
251 bp for MRE11 isoform 2. PCRs were con-
ducted on cDNA using OneTaq Quik-load master
mix with standard buffer (New England BioLabs,
MA, USA) and products were separated on a 1%
agarose (Sigma Aldrich, St. Louis, MO, USA)
gel. The gel was visualised using a Molecular
Imager Gel Doc XR system (BioRad, Hercules, CA,
USA) and the band intensities of the PCR products
analysed using Image Lab software (BioRad, Her-
cules, CA, USA). Primers for GAPDH (Forward-
ACAGTCAGCCGCATCTTCTT, Reverse- AAT-
GAAGGGGTCATTGATG) were used in a concur-
rent PCR and run next to the MRE11 isoform
amplification PCR as a control for cDNA input and
quality.
TCGA
We downloaded all RNA sequencing reads map-
ping to MRE11A from TCGA [16] using the
bam-slicing functionality of the GDC data portal.
Since the position of the SNP rs1805363 is not cov-
ered in the exome capture sequencing available in
TCGA, we downloaded the Genome-Wide Human
SNP Array 6.0 data which contains rs1805363. High
confidence calls for the genotype (Birdseed [17]
confidence score <0.1) were extracted (instances
not matching the criteria were assigned the label
‘unknown’). In total, we could obtain genotype data
for 410 samples with paired RNA sequencing data (all
primary cancer, no normal controls or metastatic sam-
ples). Isoform usage of the MRE11A locus was then
quantified using Salmon (version 0.12.0 using stan-
dard parameters [18]) using the MRE11A isoforms
described in Ensembl (version 96 [19] and Gen-
code (version 29), resulting in Transcript per Million
Read values (TPM) for each isoform. Of the ten iso-
forms described, we found five regularly expressed
in the TCGA samples. We tested a shift in relative
isoform usage of the variant samples (genotype G
vs. A) versus wild-type using an unpaired one-sided
Wilcoxon test on the relative use of each isoform,
and on the pairwise ratios of each isoform against
each other.
Cell culture and transfection
293T cells were obtained from ATCC, Manassas,
VA, USA, in 2011 and confirmed to be mycoplasma
negative by PCR in October 2016. RT112 cell
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Fig. 1. Overview of MRE11 isoform 1 and 2 structure, and the distribution of MRE11 isoformsin tumour samples.(A)Schematic illustrating
the splicing of MRE11 pre-mRNA to form MRE11 isoform 1 and 2.Exons are displayed as coloured numbered boxes. Yellow and dark blue
boxes portray exons within untranslated regions (UTR) and protein coding regions respectively. Green lines directly beneath the exon boxes
depict MRE11isoform 1 splicing and MRE11 isoform 2 splicing is described by the orange lines above. The skipping of exon 16 in MRE11
isoform 2 is highlighted by the purple dotted box. The light blue dotted box highlights the usage of an alternative splice site within exon
1, producing a shorter exon 1 sequence in MRE11 isoform 1. (B) The relative position of the rs1805363 SNP within the 5’ UTR of both
MRE11 isoforms. Relative exon sizes are based on MRE11A RefSeq accessions NM 005591.3 and NM 005590.3. Relative intron lengths
were calculated using BLAT to aligning reference mRNA sequences onto genomic DNA [29]. (C)Representative image of electrophoresis
bands produced from the PCRs conducted on cDNA from tumour samples. The 144 bp product is amplified from the MRE11 isoform 1
5’UTR and the 251 bp product is amplified from the longer MRE11 isoform 2 5’UTR. Amplification of GAPDH was run as a positive control
for all samples. (D) Quantification of tumour MRE11 isoform expression. MRE11 isoform 1 and 2 expression is displayed as a percentage
of the total amount of MRE11 in each sample. Samples are grouped according to the presence or absence of the rs1805363 A minor allele in
germline DNA. The tumour genotype is displayed where known. The proportion of MRE11 isoform 2 expression is significantly increased in
patients who are positive for the rs1805363 A minor allele compared to patients who are only positive for the G major allele (t-test p = 0.007).
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lines were obtained from DSMZ, Braunschweig,
Germany, in 2016. RT112 wildtype, RT112-MRE11
KD, RT112-full length MRE11 and RT112-MRE11
exon16 cells (see below) were confirmed to be
mycoplasma negative by PCR in September 2018.
Cell lines were used up to 20 passages from original
stock.
293T cells were maintained in high glucose
DMEM (Gibco-Thermo Fisher Scientific, CA, USA)
supplemented with 10% FBS (Thermo Fisher,
Waltham, CA, USA) without antibiotics. Cells were
maintained at 37◦C and 5% CO2 in a humidified incu-
bator. Cells were transfected in 10 cm dishes seeded
at 5x106 cells per dish, and 9g of either pLenti-full
length MRE11 or pLenti-MRE11-exon16, 4.5g
of psPAX2 (#12260; Addgene, MA, USA), and
4.5g of pMD2.G (#12259; Addgene, MA, USA)
were delivered to each dish with Lipofectamine 3000
(Thermo fisher, MA, USA) in opti-MEM (Thermo
Fisher, Waltham, CA, USA), according to manufac-
turer’s instructions. The generated lentiviral particles
were collected 48 hr following transfection and fil-
tered through a 0.45m syringe filter (SLHV033RS;
Millipore, Burlington, MA, USA). RT112-MRE11
KD cells were generated as previously described
[20], and additionally, a monoclonal cell line was
isolated from a polyclonal pool of stable cells and
expanded. RT112-MRE11 KD cells were infected
with the filtered lentiviral supernatant using 8g/ml
of polybrene. After 3 days of infection, 5g of
puromycin was added for selection with complete
media (RPMI medium supplemented with 10% FBS).
MRE11-mutated stable cell lines were established
after 96-well monoclonal selection and samples were
collected or fixed at 10 min, 30 min, 2 hr, 6 hr and
24 hr after 2Gy of Cs-137 ionising radiation using a
GSR-D1 caesium-137 irradiator (Gamma Services,
Surrey, UK).
Vectors and site-directed mutagenesis
MRE11 sequences were inserted into the vec-
tor pLenti-puro-CMV (P100022; Vigene, Rockville,
MD, USA). A QuickChange II XL Site-Directed
Mutagenesis Kit (#200521; Agilent, Santa Clara,
CA, USA) and XL10-Gold ultracompetent cells were
used for all site-directed mutageneses according to
the manufacturer’s instructions. DNA sequencing
(Source Bioscience, Nottingham, UK) was used to
confirm the mutated nucleotides and the deleted exon
16 sequences (Supplementary Figure 1).
Western blotting
Protein lysis buffer was prepared in 50 mmol/L
HEPES, 100 mmol/L NaCl, 10 mmol/L EDTA,
1% Triton X-100, 4 mmol/L Na pyrophosphate,
2 mmol/L sodium orthovanadate, 10 nmol/L NaF, and
50 mmol/L B-glycerophosphate. Cells were lysed
in lysis buffer containing a cocktail of proteinase
inhibitors (Roche, Mannheim, Germany). Protein
quantification of the lysates was performed using
a BCA protein assay (Thermo Fisher, Waltham,
MA, USA) and 30g of protein was resolved
on 4% to 20% polyacrylamide gels and trans-
ferred onto nitrocellulose membranes. The resulting
membranes were incubated with blocking buffer
(Li-cor Biosciences, Lincoln, NE, USA) and pri-
mary antibodies. The antibodies used were mouse
polyclonal anti-MRE11 (ab214; abcam, Cambridge,
UK), rabbit anti-phospho-histone H2A.X (Ser139)
(#2577; Cell Signalling Technology, Danvers, MA,
USA), and mouse monoclonal anti--actin (ab6276;
abcam, Cambridge, UK). Fluorochrome-conjugated
secondary antibodies (Li-cor Biosciences, Lincoln,
NE, USA) were used and detected by infrared scan-
ning densitometry using the Li-cor Odyssey Infrared
Detection System (Li-cor Biosciences, Lincoln, NE,
USA).
Clonogenic assay
RT112 cells and stable cell lines were plated in 6
cm culture dishes containing 4 ml of fresh medium
with appropriate numbers in triplicate (300–1,800)
and were irradiated at 0–10 Gy on the day after cell
plating and incubated for 2 weeks. Cells were stained
with crystal violet staining solution (0.5%) in 80 ml
distilled water, 20 ml methanol, and 0.5 g crystal vio-
let powder (Merck, Whitehouse station, NJ, USA).
Colonies containing more than 50 cells were counted
and the surviving fraction was determined as the total
number of colonies formed divided by the total num-
ber of cells plated multiplied by the plating efficiency,
as determined in untreated cells. Radiation survival
curves were plotted in GraphPad Prism, using the
linear-quadratic model with the equation SF = exp
–(D +D2 ), where D is a dose of radiation.
Immunoﬂuorescence
RT112 and stable cell lines were plated onto 8-
well chamber slides (734–2050; NUNC, Roskilde,
Denmark) and fixed with 100% methanol for 5 min
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at –20◦C, at each time point after IR. Then cells were
washed three times for 5 min each time in PBS. All
subsequent steps were carried out at room tempera-
ture. Samples were blocked for 30 min in blocking
buffer (1% BSA, 22.52 mg/ml glycine in PBST
(PBS + 0.1% Tween 20)). Rabbit anti-phospho-
histone H2A.X (Ser139) (#2577; Cell Signalling
Technology, Danvers, MA, USA) was diluted 1:500
in PBST and incubated overnight at 4◦C. Cells were
washed with PBS, after which secondary antibody
[AlexaFluor 568 (A11036; Thermo Fisher Scientific,
Waltham, MA, USA)] was diluted 1:2000 in PBST
and applied for 1 hr in room temperature. Cells were
washed with PBS as before and mounted by using
proLong diamond antifade mountant with DAPI
(P36962; Thermo Fisher Scientific, Waltham, MA,
USA). Cells were visualised for -H2AX immunos-
taining through confocal microscopy (Zeiss 710).
Data analysis
Clonogenic assays, western blots, and immunoflu-
orescence data are representative of three indepen-
dent experiments. For-H2AX foci kinetics,P values
were calculated using Kruskal Wallis test with Dunn’s
multiple comparisons in GraphPad Prism. Counting
of -H2AX foci was determined using Image J soft-
ware. For clonogenic assays, surviving fraction was
calculated on the basis of the number of colonies on
non-irradiated plates. Data are presented as the log
of the surviving fraction with error bars representing
the SEM.
RESULTS
We obtained 189 samples of germline DNA from
the University of Birmingham’s Bladder Cancer
Prognosis Programme which were genotyped for the
rs1805363 G > A SNP. Of these patients, 141 were
diagnosed with muscularis propria invasion (stage
T2+) and 48 with lamina propria invasion (T1). Of
the 189 samples, 22 were identified as containing
both A and G alleles, with the remainder identified as
only containing the major G (WT) allele. Loss of het-
erozygosity (LOH) within heterozygous tumours was
investigated by genotyping extracted tumour DNA,
which was available for 17 of the germline genotyped
casesidentified as positive for both A and G alleles.
LOH was identified in 7 of the 17 samples (A only
in 4/17, G only in 3/17, A and G in the remaining
10/17).
To determine the relative proportions of isoform
1 and isoform 2 in patients’ tumours, FFPE tumour
blocks were obtained for RNA extraction from 36
of the germline genotyped samples. Twelve of the
tumour blocks were not suitable for RNA extraction.
This was due to either a lack of invasive pathology in
cut sections (6/12), the area of tissue being too small
for sufficient material to be collected (5/12) or the tis-
sue being identified as highly inflamed (1/12). Of the
remaining 24 blocks, 10 were from patients’ germline
positive for both A and G alleles and 14 from patients
positive for only the G (WT) allele. RNA extracted
from patient tumours was then used to quantify the
relative expression of isoform 1 and 2 within the
samples and grouped according to germline geno-
type (Fig. 1). One sample was excluded from the
analysis due to a failure in isoform amplification. In
agreement with previous findings, MRE11 isoform
2 expression was found to be significantly higher
(p = 0.007) in patients positive for the rs1805363 A
minor allele (mean proportion of MRE11 isoform 2 in
the germline genotyped patient group containing both
A and G alleles: 19.4%) compared to patients posi-
tive for only the G major allele (mean proportion of
MRE11 isoform 2 in the G only germline genotyped
patient group: 2.3%). Isoform 2 was also found to
be generally increased in non-wild-type samples in
TCGA (p-value: <0.001), as well as in direct com-
parison to isoform 1 (p = 0.017) (see Supplementary
Table 1). Although there was a trend for variant SNPs
to correlate with isoform 2 expression, not all samples
followed this trend (Fig. 2A). Furthermore, a cluster-
ing based on the expression of all isoforms did not
separate wild-type from variant samples (Fig. 2B).
We then investigated whether the increased pres-
ence of MRE11 isoform 2 could influence cellular
radiosensitivity and DNA damage response. We used
an RT112 bladder cancer cell line knocked down for
endogenous MRE11 and re-expressing an MRE11
construct containing either the full length MRE11
coding sequence (MRE11 isoform 1) or the MRE11
coding sequence lacking MRE11 exon 16 (MRE11
isoform 2). As this question referred to the function of
the translated protein we did not include the MRE11
isoform 1 or 2 5’UTR sequences in these constructs.
Lenti-viral expression of either MRE11 isoform 1
or isoform 2 in these cells led to a greater than 2.5-fold
increase in full-length MRE11 protein level (2.61-
fold for MRE11 isoform 1, 2.53-fold for MRE11
isoform 2), which corresponds to approximately 30%
of the endogenous full-length MRE11 level in the
parental cell line (Fig. 3A).
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Fig. 2. Analysis of MRE11 isoforms in TCGA bladder cancer tumours (A)Expression values (Transcript per million, TPM, computed on
reads mapping to MRE11 only) of isoform 1 (x-axis) compared to isoform 2 (y-axis) in TCGA bladder cancer samples. Node colours indicate
variant calling for rs1805363.(B)Clustering of MRE11 isoforms. Colour intensity refers to percentage of isoform usage.
Fig. 3. Establishment of MRE11 knockdown, MRE11 full length, and MRE11 exon16 -ve cell lines, and their clonogenic survival after
irradiation(A) Western blot of RT112 cells and RT112-MRE11 knockdown cells stably transduced with lentiviruses containing either MRE11
full length or MRE11 exon16 –ve sequences and myc tag. (B) Clonogenic survival assays were performed following ionising radiation and
surviving curves were fitted using the linear-quadratic equation.
A colony survival assay was performed to deter-
mine the radiosensitivity of the MRE11 RT112 cell
lines. The MRE11 knockdown cell line displayed a
significant increase in radiosensitivity compared to
the parental RT112 cell line at doses of 2 to 10 Gy.
This was rescued by the re-expression of either the
MRE11 full length (isoform 1) (1.6-fold and 1.9-
fold reduction of parental cell survival levels at 8
and 10 Gy) or the MRE11 exon16-negative con-
struct (isoform 2) (1.6-fold and 2.3-fold reduction
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of parental cells at 8 and 10 Gy), while MRE11
knockdown cells had 62.5-fold and 52.6-fold reduc-
tion on survival compared to parental cells at 8
and 10 Gy. However, there was no significant dif-
ference in radiosensitivity between cells expressing
the full-length version MRE11 and exon16-deleted
(exon16) cells (Fig. 3B). To determine whether
exon16 cells had an altered functional response
to DSB,-H2AX foci were quantified after expo-
sure to 2Gy of IR. The level of -H2AX started to
increase 10 min after 2Gy IR regardless of MRE11
expression. It reached its peak at 30 minutes post-
IR, with significantly (1.81-fold) higher levels in the
MRE11 knockdown cells compared to the parental
cell line that persisted for 2, 6 and 24 hrs after irradia-
tion. Consistent with the level of expression achieved
compared to the parental cells, MRE11-transfected
cells showed a partial reduction in -H2AX foci at
2 hr after 2 Gy irradiation, at an intermediate level
between the parental and MRE11 knockdown cells.
The reduction in -H2AX after rescue with either the
MRE11 full length or exon16 constructs was 1.3-
fold at 30 minutes after 2 Gy IR, similar to the MRE11
protein levels achieved relative to the parental cells.
There was no significant difference in -H2AX foci
at any of the time points between the MRE11 full
length and the exon16 cells (Fig. 4A and B). More-
over, the initial -H2AX foci level (No IR) for all
four cell lines were re-achieved at the 6 hr time point.
This suggests that the absence of exon 16 has mini-
mal effects on cell survival and repair of DNA damage
after IR.
DISCUSSION
In line with our previous report on the MRE11
rs1805363 SNP in patients with invasive bladder can-
cer, we genotyped the rs1805363 status of germline
DNA and in this study provided further evidence for
a correlation between the presence of the MRE11
germline rs1805363 A minor allele and an increase in
the tumour expression of MRE11 isoform 2 over iso-
form 1. However, it would be useful to establish if the
tumour genotype is a more accurate indicator of the
expression of MRE11 isoform 2 in invasive bladder
tumours.
In TCGA, the SNP variant was even more frequent
(at 16% minor allele frequency) than reported earlier
(e.g. 11% in Teo et al; lower frequencies in differ-
ent variation studies as reported in dbGAP, including
approximately 5% in the TopMed meta-study and
approximately 8% in the European population (see
Supplementary Table 1). However, it is not possi-
ble to determine whether patients with cancer have
a higher frequency of the SNP in their germline or
whether this result reflects the somatic nature of the
TCGA data. The isoform quantification of the TCGA
data clearly supports the observation of a variant-
dependent increase of isoform 2, but not all samples
follow this trend. The bioinformatics approach to
quantify the isoforms relied on the full set of anno-
tated isoforms (in total 10) which, while allowing
a more complete picture, might also hamper the
analysis, since the algorithm might not be able to dis-
tinguish all isoforms correctly in all instances. The
results of the TCGA analysis therefore highlights the
fact that further research is required to determine how
to best quantify the MRE11 isoforms from RNA-seq
data. In addition, it would be of interest to study
other isoforms, as for example ENST00000540013.5
coding for a much shorter protein without exon 16,
which seems to be supressed in the non-wild-type
cases (Supplementary Table 1).
Given that the presence of the rs1805363 A minor
allele in the germline DNA of patients with invasive
bladder cancer was associated with worse survival
after radiotherapy [14], we hypothesised that cells
expressing increased levels of MRE11 isoform 2 may
have an altered response to ionising radiation com-
pared to cells expressingMRE11 isoform 1. However,
when we re-expressed constructs for MRE11 iso-
form 1 or 2 in a bladder a cancer cell line which
had been knocked down for endogenous MRE11 and
used assays to assess their intrinsic radiosensitivity,
no difference was observed between cells expressing
the full length coding sequence for MRE11 (MRE11
isoform 1) or cells expressing MRE11 lacking exon
16 (MRE11 isoform 2). We therefore conclude that
the presence or absence of MRE11 exon 16 may not
influence cell survival or DSB repair capacity after
IR, contrary to our initial hypothesis, although we
appreciate that our conclusions are limited by the use
of only one cell line system.
In our cellular analysis of MRE11 isoform 2 we
were interested in directly comparing the protein
function of our MRE11 constructs. Therefore, we
selected cells for our assays that stably re-expressed
our constructs. Unfortunately, this strategy did not
allow us to address whether there was a difference
in the protein stability or turnover between the two
isoforms. Ideally, the protein levels of MRE11 iso-
form 1 and isoform 2 would have been assessed in
patient samples where we had quantified the rela-
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Fig. 4. Radiation-induced formation of -H2AX foci in MRE11 full length and MRE11 exon16 -ve rescued cells(A) RT112 cells were
treated with 2 Gy irradiation and incubated at 37◦C for the times shown. Representative images are displayed with-H2AX foci in redand
blue represents DAPI staining (scale bar: 10m). (B) Statistical analyses of number of -H2AX foci per cell are shown as box and whisker
plots with 5th–95th percentiles. In total, 180 nuclei were counted per sample in 3 independent experiments. Asterisks indicate ∗P≤ 0.05, ∗∗
P≤ 0.01, ∗∗∗P≤ 0.001, and ∗∗∗∗P≤ 0.0001.
tive expression of mRNA. However, unfortunately
with no available antibody distinguishing between
the two isoforms and with only a 27aa difference
between the two protein variants, it was not possible
to reliably distinguish the isoforms using techniques
such as western blotting or immunohistochemistry.
We did have an antibody raised to exon 16 but this
unfortunately proved unsuitable for western blotting,
and so we could not verify its specificity for use in
determining the isoforms’ presence in the samples.
Interestingly, the phosphorylation of MRE11 thre-
onine 597, which resides within exon16, has been
found to promote MRE11 degradation in PTEN defi-
cient cells [21], which does suggest that in some cases
a difference in protein stability may exist between the
two isoforms.
A limitation in the system we used to investigate
the efficiency of DSB repair by MRE11 isoform 1
compared to 2 is that we only re-expressed either
MRE11 isoform 1 or 2 in our KD cells. However,
in the human tissue we analysed MRE11 isoform 1
was present in conjunction with isoform 2. There-
fore this method may be an oversimplification of the
underlying biology and expressing different ratios
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of the two isoforms may be a more representative
model in which to study their function. Indeed, in
cells, MRE11 exists as a homodimer with dimeri-
sation being critical for the correct assembly of the
MRN complex and the binding and aligning of DNA
ends [22]. It is possible that although each isoform
in this analysis was proficient for DSB repair when
expressed in isolation, a dimer comprised of the two
different isoforms may not be. The complexity of the
interactions between MRE11 and the members of the
MRN complex have been previously highlighted. It
has been proposed that as the MRN complex is a het-
erohexamer comprised of 3 protein dimers it could
exist in multiple states, where different dimer assem-
blages within the complex affect its response to DNA
damage [23].
Aside from its role in DNA damage repair, MRE11
also functions in the repair of stalled and collapsed
replication forks [24–28]. While we saw no defect
in the ability of MRE11 lacking exon16 to repair
DNA damage following ionising radiation, it may
be that this form of MRE11 is not able to function
in response to replication stress. This would be wor-
thy of further investigation and a possible reason for
the poor response of rs1805363 positive patients with
high MRE11 isoform 2 levels to radiotherapy.
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